Milsaperidone

Quick answers

What is milsaperidone?

Milsaperidone (brand Bysanti) is a second-generation antipsychotic approved in February 2026 for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder in adults.

What is Bysanti?

Bysanti is a brand name for milsaperidone.

What is Bysanti (milsaperidone) used for?

Label indications include: Schizophrenia (adults); Acute manic/mixed episodes in bipolar I disorder (adults).

What drug class is Bysanti (milsaperidone)?

Atypical Antipsychotic.

What is the mechanism of action of Bysanti (milsaperidone)?

Dopamine D2 and serotonin 5-HT2A antagonist with adrenergic α1 blockade; active metabolite of iloperidone requiring structured titration.

What strengths does Bysanti (milsaperidone) come in?

Tablets: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg.

Is Bysanti (milsaperidone) a controlled substance?

No — it is not scheduled as a controlled substance under U.S. federal law.

What is Bysanti (milsaperidone) dosing for schizophrenia?

Schizophrenia: Titrate over 7 days from 1 mg BID to a target of 6-12 mg BID (12-24 mg/day).

Is Bysanti (milsaperidone) an antipsychotic?

Yes, Bysanti (milsaperidone) is a atypical (second-generation) antipsychotic.

What is the half-life of Bysanti (milsaperidone)?

The elimination half-life of milsaperidone is approximately 26 hours (single dose); approximately 33 hours (steady state).

What is the brand name for milsaperidone?

The brand name for milsaperidone is Bysanti.

General information

As the active metabolite of iloperidone with an additional bipolar I mania indication, milsaperidone may appeal to clinicians already familiar with iloperidone's profile. The dual indication for schizophrenia and bipolar mania distinguishes it from its parent compound.

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

• High affinity at α1-adrenergic, 5-HT2A, D2, and D3 receptors.
• Moderate affinity at 5-HT6, 5-HT7, and α2C receptors.
• Minimal muscarinic and histaminergic activity limits anticholinergic side effects.

Metabolism & pharmacokinetics

• Milsaperidone is the active metabolite of iloperidone (P95, carbonyl-reduced metabolite). Both compounds interconvert and contribute to clinical effect.
• Metabolized primarily via CYP2D6 and CYP3A4; elimination half-life averages 26 hours in extensive metabolizers and 37 hours in poor metabolizers.
• Steady state is achieved within 3-4 days of regular dosing; protein binding is approximately 95%.
• CYP2D6 poor metabolizers (7-10% of Caucasians) exhibit approximately double the exposure, and dose adjustment by 50% is typically required.
• Hepatic impairment increases exposure; slower titration and close monitoring are common. Severe hepatic impairment has not been studied and use is generally avoided.

Dosing & administration

• Schizophrenia: titrate over 7 days from 1 mg BID to 6-12 mg BID (12-24 mg/day). Bipolar I mania: titrate over 5 days to 12 mg BID (24 mg/day).
• CYP2D6 poor metabolizers or strong CYP2D6 inhibitor co-therapy (fluoxetine, paroxetine, quinidine): target and maximum doses are typically reduced by 50%.
• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): dose reduction by ~50% is common, with QTc monitoring often considered.
• Strong CYP3A4 inducers (carbamazepine, rifampin): serum levels can drop significantly, risking relapse, so combinations are generally avoided.
• If therapy is interrupted for ≥3 consecutive days, titration is typically restarted from 1 mg BID to reduce hypotension risk.
• Administration: Twice-daily dosing with or without food; bedtime dosing of the higher portion may reduce orthostatic symptoms.

Adverse effects

Interactions

• Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion): dose reduction by ~50% is common; monitoring for orthostasis and QT prolongation is often increased.
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): dose reduction by ~50% is common, and ECG monitoring is often considered.
• Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort): exposure can drop substantially, so use is generally avoided.
• QTc-prolonging agents (haloperidol, ziprasidone, methadone, macrolides): ECG monitoring and electrolyte optimization are commonly considered.
• Antihypertensives or vasodilators: additive hypotension; dose adjustments and vitals monitoring may be needed.
• Alcohol and CNS depressants: increase sedation; counseling about additive risk is common, especially during titration.

Other useful information

• Orthostatic vitals are often checked at baseline, during titration, and after dose increases.
• Patient education often includes a written titration schedule and the need to restart titration if doses are missed ≥3 days.
• As the active metabolite of iloperidone, milsaperidone shares clinical considerations; clinicians familiar with iloperidone can leverage that experience. The additional bipolar mania indication expands the clinical utility.
• Routine metabolic monitoring is continued per standard SGA guidance even though average weight gain is limited overall.
• Pregnancy: Limited human data. Use is generally reserved for situations where benefits outweigh risks, and neonates are monitored for EPS/withdrawal. Caution is advised with breastfeeding.

References